Not a recommended panel for the diagnosis of antiphospholipid syndrome (APS). The Cardiolipin Antibodies, IgG and IgM (0099344) is preferred.
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Within 24 hours
New York DOH Approval Status
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Plasma or other body fluids. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
|0050901||Cardiolipin Antibody, IgG||Effective November 15, 2021
|0050902||Cardiolipin Antibody, IgM||Effective November 15, 2021
|0098358||Cardiolipin Antibody, IgA||Effective August 18, 2014
The persistent presence of IgG and/or IgM cardiolipin (CL) antibodies in moderate or high levels (greater than 40 GPL and/or greater than 40 MPL units) is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM CL antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). Lower positive levels of IgG and/or IgM CL antibodies (above cutoff but less than 40 GPL and/or less than 40 MPL units) may occur in patients with the clinical symptoms of APS; therefore, the actual significance of these levels is undefined. Results should not be used alone for diagnosis and must be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests.
|Component Test Code*||Component Chart Name||LOINC|
|0050901||Cardiolipin Antibody IgG||3181-5|
|0050902||Cardiolipin Antibody IgM||3182-3|
|0098358||Cardiolipin Antibody IgA||5076-5|
- aCL Antibodies
- aCL Antibody
- Anticardiolipin Antibodies
- Cardiolipin Antibodies, IgA, IgG, IgM